Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?

Fernando Kemta Lekpa, Bertrand Hugo Mbatchou Ngahane, Sylvain Raoul Simeni Njonou, Hermine Fouda, Marie Patrice Halle, Yacouba Mapoure Njankouo, Anastase Dzudie, Simeon Pierre Choukem, Henry Namme Luma

Corresponding author: Fernando Kemta Lekpa, Internal Medicine Department, Douala General Hospital, Douala, Cameroon. fklekpa@yahoo.fr

Received: 29 Mar 2021 - Accepted: 08 Apr 2021 - Published: 15 Apr 2021

Keywords: Hydroxychloroquine, rituximab, COVID-19, randomized controlled trials

Copyright: Fernando Kemta Lekpa et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Fernando Kemta Lekpa et al. Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus? Pan African Medical Journal. 2021;38(372). 10.11604/pamj.2021.38.372.29087

Available online at: https://www.panafrican-med-journal.com//content/article/38/372/full

Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?

Fernando Kemta Lekpa1,2,3,6, Bertrand Hugo Mbatchou Ngahane1, Sylvain Raoul Simeni Njonou2,3, Hermine Fouda1, Marie Patrice Halle1, Yacouba Mapoure Njankouo1, Anastase Dzudie2,3, Simeon Pierre Choukem1,2,3,4, Henry Namme Luma1

1Internal Medicine Department, Douala General Hospital, Douala, Cameroon, 2Department of Internal Medicine and Specialties, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon, 3The University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19), Dschang, Cameroon, 4Health and Human Development (2HD) Research Network, Douala, Cameroon

6Corresponding author
Fernando Kemta Lekpa, Internal Medicine Department, Douala General Hospital, Douala, Cameroon
Abstract

Rituximab (RTX), a chimeric monoclonal anti-CD20 antibody has become part of the standard therapy for patients with CD20-expressing B-cell lymphoma and rheumatoid arthritis. After encouraging results with open studies in systemic lupus erythematosus (SLE), RTX has not shown its effectiveness in randomized controlled trials. However, its efficacy has been validated in renal, hematological, and neuropsychiatric disorders. Understanding the history of RTX in SLE would be instructive in the hydroxychloroquine (HCQ) saga in COVID-19. Three steps would be necessary and sufficient before definitively closing the debate: 1) determine the effective and safe dose of HCQ, as well as the minimum duration of treatment in COVID-19; 2) define the profile of patients in whom HCQ would be more likely to be effective (especially in asymptomatic patients and/or at the onset of the first signs of the disease) and 3) conduct one or more multicentre RCT to evaluate the efficacy and safety of HCQ in COVID-19 in SSA.

Commentary

Sir, Rituximab (RTX), a chimeric monoclonal anti-CD20 antibody, has become part of the standard therapy for patients with CD20-expressing B-cell lymphoma and rheumatoid arthritis. The first data from observational studies had given satisfactory results in patients with systemic lupus erythematosus (SLE) refractory to conventional treatments [1]. These results have not always been confirmed by randomized controlled trials (RCT). However, positive results have been described for some locations in this non-specific systemic organ auto-immune disease. Thus, RTX is currently used off-label, particularly in patients with severe renal, hematological and/or neuropsychiatric disease refractory to other immunosuppressive therapies or in patients with contraindications to these drugs [2]. More so, RTX is included in the 2019 updates of the European League Against Rheumatism (EULAR) recommendations for the management of SLE [3].

Although hydroxychloroquine (HCQ) is recommended for all patients with SLE [3], this drug has found a new usage with the COVID-19 disease. This COVID-19 made HCQ the most publicized drug of 2020 [4]. After the positive results from observational studies on HCQ in COVID-19 [5], wide use of this drug has been observed worldwide [4]. Subsequently, RCT, systematic reviews and meta-analysis with contradictory results were also published. The Cochrane review declared HCQ persona non grata in COVID-19, thus signing game over by showing that HCQ has little or no effect on the risk of death and probably no effect on the progression to mechanical ventilation for people infected with COVID-19 [6].

HCQ with or without azithromycin has been widely used as a treatment protocol for COVID-19 by many countries in SSA, in the absence of controlled trials and with different dosage (Table 1) [7, 8]. The same is true for some herbal medicines which have been widely used in the absence of evidence of their effectiveness [9]. The limited access to therapeutic resources in SSA [10] leads us to ask ourselves once again the following question: apart from the young age of Africans, is the low mortality in SSA linked to the wide use of herbal medicines and dietary therapy or the result of the effectiveness of HCQ in COVID-19 in this population? To find out, it would be imperative not to consider the recommendation of the Cochrane review to no longer conduct further trials on HCQ for the treatment of COVID-19, but to conduct clinical trials on available drugs and herbal medicines accessible in SSA at a cost that the community and African countries can afford.

Understanding the history of RTX in SLE would be instructive in the HCQ saga in COVID-19. In the absence of data on the populations of SSA from the “Solidarity” clinical trial, three steps would be necessary and sufficient before definitively closing the debate: 1) determine the effective and safe dose of HCQ, as well as the minimum duration of treatment in COVID-19; 2) define the profile of patients in whom HCQ would be more likely to be effective (especially in asymptomatic patients
and/or at the onset of the first signs of the disease); and 3) conduct one or more multicentre RCT to evaluate the efficacy and safety of HCQ in COVID-19 in SSA.

### Competing interests

The authors declare no competing interests.

### Authors' contributions

Conception, design and drafting of the manuscript: FKL, BHMN, SRSN, SPC and HNL. Reviewing manuscript: FKL, BHMN, SRSN, HF, MPH, YMN, AD, SPC and HNL. All the authors read and approved the final version of the manuscript for publication.

### Table

**Table 1**: different dosages of hydroxychloroquine in COVID-19 used at the Douala General Hospital, Douala, Cameroon*

### References

1. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8): 2458-66. PubMed | Google Scholar
2. Duxbury B, Combesure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22(14): 1489-503. PubMed | Google Scholar
3. Fanouriakis A, Kostopoulos M, Alunno A, Aringer M, Bajema I, Boletis JN et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6): 736-745. PubMed | Google Scholar
4. Berlivet L, Löwy I. Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. Med Anthropol Q. 2020;34(4): 525-541. PubMed | Google Scholar
5. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1): 105949. PubMed | Google Scholar
6. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021;2: CD013587. Google Scholar
7. Belayneh A. Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation. Res Rep Trop Med. 2020;11: 61-72. PubMed | Google Scholar
8. Ashinyo ME, Duti V, Dubik SD, Amegah KE, Kutsoati S, Oduro-Mensah E et al. Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. Pan Afr Med J. 2020 Sep 15;37(Suppl 1): 9. PubMed | Google Scholar
9. Akindele AJ, Agunbiade FO, Sofidiya MO, Awodele O, Sowemimo A, Ade-Ademilua O et al. COVID-19 Pandemic: A Case for Phytomedicines. Nat Prod Commun. 2020 Aug;15(8): 1934578X20945086. PubMed | Google Scholar
10. Njonjou SRS, Ouankou CN, Lekpa FK, Balti EV, Choukem SP. Availability of drugs for severe COVID-19 in sub-Saharan Africa. Pan Afr Med J. 2020 May 26;35(Suppl 2): 48. PubMed | Google Scholar
**Table 1:** different dosages of hydroxychloroquine in COVID-19 used at the Douala General Hospital, Douala, Cameroon*

| Date                          | Hydroxychloroquine, 200 mg                      |
|-------------------------------|-------------------------------------------------|
| From March 2020 to May 2020   | 1 tablet three times a day for 10 days          |
| From June 2020 to August 2020 | 1 tablet three times a day for 5 to 7 days      |
| From September 2020 to February 2020 | 1 tablet twice a day for 5 days                  |
| From March 2020 to date       | 1 tablet three times a day for 5 to 7 days      |

*Between April 2020 and March 2020, the doses of hydroxychloroquine (associated with azithromycin) were determined by the endowment offered by the Ministry of Health of Cameroon.*